Clinical Trial: Perioperative sintilimab, ipilimumab N01, and SOX for HER2-negative, PD-L1 CPS >=1, MSS/pMMR, locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Perioperative sintilimab, ipilimumab N01, and SOX for HER2-negative, PD-L1 CPS >=1, MSS/pMMR, locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135518

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: The First Medical Center of the Chinese PLA General Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=327969

Published by HT Digital Content Services with permission from Health Daily Digest....